1. Introduction {#sec1}
===============

Type 2 diabetes is characterized by multiple metabolic abnormalities including insulin resistance and beta-cell dysfunction which precede and predict the onset of the disease [@bib1], [@bib2]. Metabolic function continues to deteriorate after diagnosis, leading to worsening hyperglycemia and necessitating insulin therapy in many cases. The progression of type 2 diabetes is thought to be due to a decline in pancreatic islet beta-cell function which can be explained by considering two components: 1) a "reversible" component due to the metabolic milieu (*e.g.* glucotoxicity, lipotoxicity), and 2) an "irreversible/intrinsic" component (*e.g.* loss of beta-cell capacity/mass due to beta-cell death), each independently contributing to the pathological process of the disease [@bib3], [@bib4], [@bib5].

Short-term (two to four week) intensive insulin therapy (IIT) administered early in the course of type 2 diabetes acutely improves beta-cell function by eliminating glucotoxicity and lipotoxicity [@bib6], [@bib7], [@bib8], [@bib9]. Remarkably, this strategy can induce "glycemic remission" in some patients who can subsequently maintain normoglycemia without antidiabetic drugs for up to 1--2 years [@bib10]. However, this beneficial effect is not seen in all patients [@bib11]. Similarly, short-term IIT is also effective in patients with established type 2 diabetes of longer duration, albeit with more variability in the response [@bib12]. This heterogeneity in the response to short-term IIT may reflect varying contributions of reversible and irreversible beta-cell dysfunction, components that cannot be determined using clinical parameters or conventional measures of beta-cell function. Thus, the identification of biomarkers that can predict the response to short-term IIT and other therapeutic interventions would be valuable for improving treatment decisions and outcomes. Such biomarkers might also provide insight into novel molecular mechanisms involved in disease pathogenesis.

MicroRNAs (miRNAs) are endogenous, noncoding RNAs that are abundantly expressed in most cell types and tissues and play important roles in the regulation of a broad spectrum of physiological and pathological processes, including diabetes [@bib13], [@bib14], [@bib15], [@bib16]. Altered miRNA levels in the circulation have been associated with a variety of disease states including obesity [@bib17], [@bib18], [@bib19], [@bib20], [@bib21] and diabetes [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27]. We hypothesized that circulating levels of miRNAs implicated in beta-cell dysfunction and insulin resistance (*e.g.*, involving adipose tissue, liver, skeletal muscle) might be useful to predict responses to therapies such as short-term IIT. To test this hypothesis, we assessed changes in a panel of miRNAs implicated in diabetes in response to short-term IIT in patients with early type 2 diabetes and explored potential mechanisms underlying the reversibility of beta-cell dysfunction. This study is the first assessing the miRNA response to short-term IIT and offers novel mechanistic insights into the pathophysiology of beta-cell dysfunction in early type 2 diabetes.

2. Methods {#sec2}
==========

2.1. Study population {#sec2.1}
---------------------

The study population consisted of 24 adult patients with early type 2 diabetes who underwent short-term IIT to determine eligibility for randomization in the **LI**raglutide and **B**eta-cell **R**ep**A**ir (LIBRA) Trial ([clinicaltrial.gov](http://clinicaltrial.gov){#intref0015} identifier: [NCT01270789](NCT01270789){#intref0020}) [@bib4], [@bib11], [@bib28]. The LIBRA trial included participants with 1) duration of diabetes ≤7 years, 2) treatment with none or up to two oral antidiabetic medications (which were stopped before starting IIT), and 3) hemoglobin HbA1c at screening between 5.5 and 9.0% inclusive if on oral antidiabetic medications or between 6.0 and 10.0% inclusive if not on antidiabetic medications. Exclusion criteria included insulin therapy, renal dysfunction, hepatic dysfunction, malignancy and chronic infection. The study protocol was approved by the Mount Sinai Hospital Research Ethics Board, and all participants provided written informed consent.

2.2. Study design {#sec2.2}
-----------------

In the LIBRA trial [@bib28], 63 participants underwent 4-weeks of intensive insulin therapy (IIT). On the final day of IIT, the last insulin dose was the bolus insulin before dinner, with no bedtime basal insulin. To be eligible for randomization, participants needed to be able to maintain fasting venous glucose \<7.0 mmol/l the next morning, reflecting the capacity of endogenous insulin secretion to maintain fasting glucose in the non-diabetic range. The achievement of this threshold was previously shown to identify reversibility of beta-cell dysfunction in response to IIT [@bib12]. Of the 63 LIBRA participants, there were 12 individuals who did not achieve this threshold and hence were not eligible for randomization. These 12 individuals comprised the nonresponder (NR) group for the current study (this study). Conversely, the responder (R) group was comprised of the 12 LIBRA participants who had the largest improvement in beta-cell function from baseline to the post-IIT assessment (as defined by the percentage increase in Insulin Secretion-Sensitivity Index-2 (ISSI-2)). While there was no prospective measure of efficacy of IIT in the current analysis, it should be recognized that the beneficial effect of IIT on beta-cell function in early type 2 diabetes has been well-established in previous studies, including a meta-analysis of the studies comprising this literature [@bib10]. In the current study, all participants thus underwent assessment of beta-cell function before and after IIT, which enabled systematic assessment of the impact of IIT on beta-cell function and stratification of participants into responders and nonresponders on this basis.

The specific short-term IIT protocol, methods for laboratory measurements, and calculation of physiologic indices performed in this trial are described elsewhere [@bib4], [@bib11], [@bib28]. Glucagon measurements were performed using a glucagon enzyme-linked immunosorbent assay 10-1271-01 from Mercodia (Uppsala, Sweden) as recently described [@bib29]. Beta-cell function was measured with the ISSI-2 index, which was the primary outcome measure in the LIBRA Trial [@bib28]. In addition, other indices of beta-cell function and insulin resistance were calculated from the OGTT, including the ΔISR~0-120~/ΔGluc~0-120~×Matsuda index and the homeostatic model assessment of insulin resistance (HOMA-IR) [@bib4], [@bib11], [@bib28]. miRNA was isolated from the fasting baseline pre-IIT OGTT and post-IIT OGTT plasma samples. A custom panel of 94 miRNAs ([Supplementary Table ST1](#appsec4){ref-type="sec"}) reported to play roles in metabolically-involved tissues such as adipose, brain, kidney, liver, muscle, and pancreas was measured by real-time PCR. All baseline clinical and biochemical data was used to generate a classifier with predictive value by implementing a machine learning approach based on the random forest algorithm [@bib30] (see Methods section: [Predictive modeling](#sec2.4){ref-type="sec"}). To gain additional biological insight of the mechanism of response to short-term IIT, we conducted differential miRNA expression analysis by implementing mixed-effect models for repeated measures (see Methods section: [Statistical analysis](#sec2.6){ref-type="sec"}) and miRNA--mRNA interaction network analysis (as described in the Methods section: [Functional network analysis](#sec2.5){ref-type="sec"}).

2.3. Measurement of plasma miRNAs {#sec2.3}
---------------------------------

miRNAs from 200 μl plasma were extracted using the miRNeasy Serum/Plasma Kit (Qiagen, Hilden, Germany), reverse transcribed, preamplified, and measured by quantitative real-time PCR using TaqMan^®^ reagents and ViiA-7^®^ instrument from ThermoFisher Scientific (Waltham, MA), following the manufacturer\'s instructions. Custom TaqMan^®^ Array MicroRNA Cards from a single production batch were used. Data was analyzed using the *HTqPCR* package in the R 3.5.1 statistical computing environment [@bib31]. Data from each sample were first normalized to the levels of recovered spike-in cel-miR-39, then subjected to quantile normalization using the *normalizeCtData* function. The median of the quantile-normalized data for the NR group, pre-IIT time point, was then subtracted from each quantile-normalized value to generate −ΔΔCt data equivalent to log2 fold change data (denoted herein logFC). As hemolysis during plasma isolation could contaminate the specific pool of circulating miRNAs and contribute to degradation of sample quality [@bib32], its impact was assessed by calculating the difference in logFC values between erythrocyte-enriched miR-451 and reference miR-23a-3p (hemolysis score = logFC~miR-451~ − logFC~miR-23a-3p~; equivalent to the log2 ratio between miR-451 and miR-23a-3p), which can detect very low levels of hemolysis [@bib33], [@bib34]. A hemolysis score lower than 7 was required by study design for samples to be included in the final analysis. Only miRNAs with greater than 2-fold baseline-adjusted differences between R and NR groups were included in the reported differential abundance analysis.

2.4. Predictive modeling {#sec2.4}
------------------------

To the limitations of a small sample size, we selected a machine learning approach based on the random forests (RF) method, which implements an out-of-bag ("bagging") technique to monitor error and ensure unbiased prediction with reduced risk of overfitting [@bib30]. As reported by [@bib30], "by using bagging in tandem with random feature selection, the out-of-bag error estimate is as accurate as using a test set of the same size as the training set. Therefore, using the out-of-bag error estimate removes the need for a set aside test set." [@bib30] In short: each new training set is drawn, with replacement, from the original training set (with each bootstrapped training set leaving about one-third of the instances out -- the out-of-bag (OOB) set); then a tree is grown on the new training set using random feature selection. Furthermore, because the RF variable selection process uses only a small random subset of predictor variables for each tree split in the classification tree, the technique can handle the "small *n* large *p*" problem, where the number of predictor variables (*p*) is greater than the number of subjects (*n*) [@bib35]. Regarding the diagnosis of human disorders, it has been demonstrated that, by means of the repeated random sampling from the learning data, RF automatically generates realistic estimates of the prediction accuracy on validation data [@bib35], [@bib36].

For our analysis, the RF algorithm was implemented using the *randomForest* package [@bib37] in the R environment. Only baseline values for all profiled miRNAs and clinical and metabolic measures were included as variables for tree splitting and classification. A twofold-iterative process of repeated, sequential backward elimination (SBE) [@bib38] was implemented. Each repetition of SBE (the "inner loop") consisted of successive cycles of RF classification whereby the less informative variable (as calculated by the Gini variable importance index) was eliminated after every cycle, until a single variable remained in the classifier. The number of trees (*ntree*) in the forest was always set to 5000 and the number of variables to be randomly sampled at each tree split (*mtry*) set equal to the total number of variables included in the given SBE "inner cycle". The OOB prediction error rate calculated for each instance of the RF classifier was recorded and the instance(s) generating the lower error rate selected as the optimal RF classifier(s) for the given SBE repetition. The SBE process was repeated 100 times (the "outer loop"), while choosing a distinct random number generator seed for each "outer cycle". The collection of optimal RF classifiers with minimal OOB error rates for all 100 repetitions of the SBE process was then summarized and the most frequent instance of the RF classifier consistently producing the lowest OOB error rate was identified. Performance and sensitivity analysis of the best classifier was evaluated and visualized using the *ROCR* package in the R environment. ROC curves were generated by using the random forest responder/nonresponder vote fractions (based on the OOB data) as prediction scores to construct the ROC curves by stepping through different thresholds for calling responder versus nonresponder. By comparing these predictions based on the out-of-bag data to their known class, estimates of the performance of the classifier can be obtained.

2.5. Functional network analysis (FNA) {#sec2.5}
--------------------------------------

Our previous experience and that from others studying disparate molecular mechanisms regulated by miRNAs indicate that global biologically significant miRNA-driven regulatory events commonly occur in a coordinated/cooperative fashion [@bib39], [@bib40], [@bib41], [@bib42], [@bib43], [@bib44], [@bib45], [@bib46]. This process can be readily described by a compact network of interactions between relevant miRNAs and corresponding "miRNA-overtargeted" genes [@bib40], [@bib42], [@bib43], [@bib44], [@bib45]. The "overtargeted" genes in a particular network appear to interact with a significantly higher number of miRNAs than expected by chance (as determined by hypergeometric tests of network proportions compared to the respective proportions in the miRNA--target interaction universe/background). In this study, we similarly conducted miRNA-overtargeting analyses following our published methodology [@bib40], [@bib42], [@bib44], [@bib45]. Significance of the cooperative (more than 1 miRNA targeting a given gene) and overtargeting effect (significant higher number of miRNA-targeting events than expected by chance on a given gene) was assessed by comparing IIT-specific network proportions and relevant number of events against a collection of 10,000 simulated equivalent random networks. The list of validated targets supported by strong experimental evidence (*i.e.*, reporter assay or Western blot) used for this analysis was downloaded from miRTarBase (file: miRTarBase_SE_WR.xls) using the *SpidermiR* package [@bib47]. Interaction networks were constructed using Cytoscape 3.5.1 [@bib48]. Enrichment of gene ontology annotations among sets of overtargeted genes was assessed using the *GOCluster_Report* function of the *systemPipeR* package [@bib49] in the R environment.

2.6. Statistical analysis {#sec2.6}
-------------------------

Data normality was tested with the Shapiro--Wilk test. Data were log or square root transformed to approximate normality when necessary. Differences in baseline clinical characteristics were assessed using the Welch two sample t test (for continuous variables) or the Fisher exact test (for categorical variables). Standard Pearson\'s correlations between baseline levels of clinical/metabolic variables and the percent change in ISSI-2 were calculated to identify potential confounding covariates. For assessment of longitudinal differences in clinical, metabolic, and circulating miRNA variables, mixed-effect models for repeated measures were implemented using the *lme4* package. Age, duration of diabetes, baseline HbA1c, baseline AUC glucagon, and baseline HOMA-IR measures were included in the model as covariates to adjust for potential confounding effects, given their relevant correlations with the percent change in ISSI-2 (absolute \|r\| \> 0.4, *P* \< 0.05). Post-hoc analysis was performed using the *phia* package. Partial correlations adjusting for the same covariates, were calculated using the *ppcor* package. Calculated effects and partial correlations were considered significant at *P* \< 0.05. False discovery rates (FDR) correcting for multiple testing were calculated using the Benjamini-Hochberg correction. Principal component analysis (PCA) using functions from the *HTqPCR* packages was used for high dimensional assessment and visualization of miRNA expression changes.

2.7. Power calculation {#sec2.7}
----------------------

Based on our data using equivalent miRNA profiling technology, we previously determined that a minimum sample size of N = 11 subjects per group will detect a 1.5-fold change in the levels of circulating miRNAs with 80% power at a two-sided significance level α = 0.05 [@bib50], [@bib51]. This study, with a slightly larger sample size (N = 12 per group) and a larger effect size required as per study design (miRNA fold change between groups greater than two), was designed to detect significant differences with greater than 80% statistical power.

3. Results {#sec3}
==========

3.1. Study participants {#sec3.1}
-----------------------

[Table 1](#tbl1){ref-type="table"} shows the baseline characteristics of the study cohort and highlights baseline group differences and correlations to the primary outcome variable, namely percent change in ISSI-2. These baseline imbalances (in duration of diabetes, HbA1c, HOMA-IR and AUC glucagon, *P* \< 0.05) and most notably, the existence of significant correlations (absolute \|r\| \> 0.4, *P* \< 0.05) between the percent change in ISSI-2 and the baseline levels of HbA1c, AUC glucagon, and age, respectively, identified these variables as potential confounders that needed to be adjusted for during statistical modeling.Table 1Baseline characteristics of the study cohort.Table 1A. Baseline characteristicsLevelNonresponder (n = 12)Responder (n = 12)*P* valueGender (%)Female4 (33.3)3 (25.0)1Male8 (66.7)9 (75.0)Ethnicity (%)Other2 (16.7)2 (16.7)1White10 (83.3)10 (83.3)Age (years)62.8 (8.3)56.0 (10.2)0.085Duration of diabetes (years)^†^4.5 (2.3)2.3 (2.4)0.026Pre-study metformin (%)02 (16.7)5 (41.7)0.369110 (83.3)7 (58.3)Pre-study sulfonylurea (%)010 (83.3)11 (91.7)112 (16.7)1 (8.3)Pre-study oral agents (%)02 (16.7)5 (41.7)0.369110 (83.3)7 (58.3)BMI (kg/m^2^)28.7 (4.6)30.7 (4.1)0.283Waist circumference(cm)97.9 (10.2)105.5 (11.8)0.104HbA1c (%)^§^6.7 (0.4)7.6 (1.2)0.022Fasting glucose (mmol/L)7.6 (1.1)7.5 (1.6)0.883Fasting insulin (mmol/L)^§^91.9 (59.6)159.7 (149.5)0.058Fasting glucagon (Mercodia) (mmol/L)6.2 (2.3)7.9 (3.5)0.169AUC glucagon (Mercodia)19.3 (4.6)27.5 (9.5)0.0132-hour glucose on OGTT (mmol/L)17.3 (2.5)16.1 (4.0)0.391HOMA IR^§^4.5 (3.1)7.5 (6.5)0.086ISSI-2113.0 (31.4)135.0 (62.7)0.289ISR0-120/Gluc0-120×Matsuda index0.10 (0.04)0.09 (0.07)0.698B. Standard baseline correlations to % change in ISSI-2ncor*P* valueHbA1c^§^240.692.1E-04AUC glucagon (Mercodia)240.540.007Age24−0.440.032Duration of diabetes^†^24−0.440.033HOMA IR^§^240.420.044Waist circumference240.360.081Fasting insulin^§^240.360.082Fasting glucagon (Mercodia)240.350.093Fasting glucose240.310.141BMI240.290.171ISR0-120/Gluc0-120×Matsuda24−0.290.1732-hour glucose240.130.537ISSI-224−0.120.572[^2][^3]

3.2. Improvements in beta-cell function and insulin sensitivity in response to short-term IIT {#sec3.2}
---------------------------------------------------------------------------------------------

As reported in the parent trial [@bib28] and by selection in the current secondary analysis, people in the R group experienced a dramatic increase in ISSI-2 (greater than 2-fold increase), whereas people in the NR group displayed a nonsignificant reduction (Group-by-Time interaction effect FDR \< 0.001, [Supplementary Table ST2](#appsec4){ref-type="sec"}), even after adjusting for confounding effects of age, duration of diabetes, and baseline levels of HbA1c, HOMA-IR, and AUC glucagon. Notably, insulin resistance (as measured by the HOMA-IR index) significantly improved in the R group only (Group-by-Time interaction effect FDR \< 0.01, [Supplementary Table ST2](#appsec4){ref-type="sec"}). In addition, people that responded to short-term IIT significantly reduced their fasting glucose and insulin levels and were able to significantly reduce their levels of glycated hemoglobin HbA1c by close to a full percent unit on average, as compared to the respective baseline levels (all three comparisons displaying Group-by-Time interaction effects with *P* ≤ 0.0268 and FDR ≤ 0.0603, [Supplementary Table ST2](#appsec4){ref-type="sec"}). Although to a lesser extent, short-term IIT also reduced HbA1c levels in the NR group resulting in a significant Time effect for this measure (*P* = 0.001, FDR \< 0.01).

3.3. MiRNA-based score of plasma quality {#sec3.3}
----------------------------------------

The quality of the initial plasma samples was assessed by calculating a hemolysis score per sample, as described in [Material and Methods](#sec2){ref-type="sec"}. All samples produced hemolysis scores below five ([Supplementary Figure SF1](#appsec4){ref-type="sec"}). Therefore, following reported guidance [@bib33], [@bib34], the risk of contamination by hemolysis was considered insignificant.

3.4. Baseline abundance of miR-145-5p, miR-29c-3p, together with baseline measures of glycated hemoglobin HbA1c accurately predict response to short-term IIT {#sec3.4}
-------------------------------------------------------------------------------------------------------------------------------------------------------------

To assess the potential of circulating miRNAs and clinical/metabolic measures to predict, at baseline, responses to short-term IIT, we implemented a comprehensive classification approach based on an RF algorithm using the *randomForest* package in the R environment. By implementing 100 iterations of an SBE approach, 159 optimal classifiers with minimal cross-validated error rate (OOB error rate = 8.3%) were generated. Baseline measurements of the trio miR-145-5p, miR-29c-3p, and HbA1c produced the best classifier 100 percent of the time, while the simpler classifier containing miR-145-5p and miR-29c-3p also attained the lowest error rate but only 56 percent of the time. A third more complex classifier including the above-mentioned trio and miR-326 also attained the lowest error rate but with a 2 percent frequency only. No combination of clinical parameters only (excluding miRNAs) generated an optimal classifier. Therefore, the RF classifier based on baseline measures of miR-145-5p, miR-29c-3p, and HbA1c was selected as the best RF classifier of response to short-term IIT. [Figure 1](#fig1){ref-type="fig"} and [Supplementary Figure SF2](#appsec4){ref-type="sec"} show the longitudinal data for the three features comprising the best classifier and a variety of performance measures demonstrating the high sensitivity (area under the receiver operator characteristic AUC = 0.951) and accuracy (positive and negative predictive values both equal to 91.7%) of the classifier. Although the baseline-adjusted changes in miR-145-5p and miR-29c-3p in response to short-term IIT were not significantly different between the two groups as per our study criteria ([Table 2](#tbl2){ref-type="table"}), there was a trend (Group-by-Time interaction *P* = 0.0547) for miR-145-5p to differentially increase with time in the responder group. However, the median post-therapy miR-145-5p level in this group was still lower than the nonresponder level ([Figure 1](#fig1){ref-type="fig"}A). Importantly, the baseline levels of plasma miR-145-5p significantly correlated with the percent change in ISSI-2 (r = −0.66, *P* = 0.0005; [Figure 1](#fig1){ref-type="fig"}D upper panel), the change in HbA1c (r = 0.48, *P* = 0.0164; [Figure 1](#fig1){ref-type="fig"}E, upper panel), and with the change in fasting glucose levels (r = 0.51, *P* = 0.0101; [Figure 1](#fig1){ref-type="fig"}F, upper panel). These correlations support the identification of miR-145-5p as a key variable in the RF classifier predictive of short-term IIT response and indicate that the lower the baseline levels of circulating miR-145-5p, the larger the subsequent short-term IIT-driven improvement in beta-cell function (as estimated by ISSI-2), reduction in HbA1c levels, and reduction in fasting glucose levels. Additionally, baseline levels of miR-145-5p significantly correlated with baseline levels of HbA1c (r = −0.59, *P* = 0.0024; [Figure 1](#fig1){ref-type="fig"}E, lower panel) and insulin resistance, as indicated by the HOMA-IR index (r = −0.48, *P* = 0.0183; [Figure 1](#fig1){ref-type="fig"}G, lower panel).Figure 1Identification of an optimal miRNA classifier for response to short-term IIT and summary of performance measures following an iterative random forests (RF) approach. (**A--C**) Dual plots for features comprising the best classifier of response. (**D--G**) Correlations between baseline levels of miR-145-5p and changes in measures of beta cell function and glucose control. ISSI-2 was the main outcome measure of beta-cell function, in the parent LIBRA trial, in response to short-term IIT. (**H**) Sensitivity analysis using the receiver operator characteristic curve (ROC). (**I**) Odds ratio plot for the classification using the best RF classifier. (**J**) Confusion matrix for the best RF classifier. (**K**) Performance measures for the best RF classifier. Orange-filled circles represent individual values for Responder (R) group. Blue-filled circles represent individual values for Nonresponder (NR) group. AUC: area under the ROC curve; PPV: positive predictive value; NPV: negative predictive value; FPR: false positive rate; FNR: false negative rate.Figure 1Table 2Several miRNAs are differential abundant in the circulation of participants in responders and nonresponders.Table 2Nonresponders (NR) (n = 12)Responders (R) (n = 12)*P* valuesFDR valuesPrePostPrePostGroupTimeGroup-by-TimeGroupTimeGroup-by-Time**Pattern A**miR.1920.0 (−3.2, 3.5)0.9 (−1.2, 3.2)2.0 (−1.5, 3.3)−1.6 (−5.7, 1.9)0.07590.5175**0.0004**0.40890.6116**0.0104**miR.320b0.0 (−0.8, 2.0)0.2 (−0.8, 2.7)0.7 (−0.4, 1.6)−0.1 (−1.6, 1.0)0.14890.4613**0.0325**0.48390.5825**0.2028**miR.1950.0 (−2.3, 1.4)0.7 (−0.1, 2.4)0.3 (−0.1, 1.7)0.4 (−0.5, 2.5)0.11010.0018**0.0364**0.40890.0156**0.2028**let.7a0.0 (−1.7, 0.5)−0.4 (−3.5, 0.5)−0.7 (−1.5, 0.9)−0.2 (−1.1, 0.9)0.74380.0562**0.0384**0.92050.1624**0.2028**miR.1380.0 (−3.2, 7.8)−3.0 (−3.6, 6.5)−0.9 (−3.6, 6.5)4.4 (−3.5, 7.1)0.71290.1627**0.0390**0.92050.3525**0.2028Pattern B**miR.20a0.0 (−0.5, 1.7)1.3 (0.9, 2.6)0.3 (−0.3, 2.6)1.5 (−0.1, 2.6)0.2863**0.0001**0.39050.6203**0.0026**0.7529let.7b0.0 (−1.1, 0.3)0.6 (−0.1, 1.9)−0.1 (−0.8, 0.8)0.9 (0.6, 2.2)0.3767**0.0002**0.65320.7534**0.0026**0.7949miR.8020.0 (−3.6, 4.2)−3.3 (−5.1, 2.8)−1.0 (−3.6, 2.2)−4.1 (−5.0, 6.1)0.4783**0.0031**0.39590.8291**0.0201**0.7529miR.34a0.0 (−3.4, 2.2)−1.1 (−4.3, 1.9)−0.5 (−2.0, 1.7)−1.3 (−3.6, 0.7)0.8851**0.005**0.73570.9205**0.026**0.8317miR.1440.0 (−6.1, 3.9)3.1 (−1.9, 4.7)−0.5 (−6.8, 4.1)2.4 (−2.1, 3.9)0.8685**0.0117**0.91940.9205**0.0507**0.9562miR.1830.0 (−7.5, 1.6)1.7 (−6.7, 4.0)0.9 (−2.9, 3.0)1.2 (−2.9, 3.5)0.0725**0.0191**0.18320.4089**0.0709**0.5954miR.15b0.0 (−0.4, 2.0)−0.6 (−2.9, 0.7)−0.2 (−3.1, 0.7)−0.9 (−4.2, 2.9)0.7236**0.0331**0.40540.9205**0.1076**0.7529**Predictive**miR.1450.0 (−0.9, 0.5)0.1 (−1.5, 0.6)−0.8 (−2.0, 0.7)−0.4 (−1.4, 0.8)0.27020.34570.05470.54040.34570.1094miR.29c0.0 (−1.1, 0.4)0.5 (−0.6, 2.2)0.5 (−0.8, 1.1)0.6 (−0.2, 1.8)0.56490.00570.44150.56490.01140.4415**Correlative**miR.483.5p0.0 (−1.1, 0.7)−0.6 (−2.1, 0.2)0.6 (−1.2, 1.9)−0.6 (−1.8, 0.4)0.24230.00410.13760.82110.01780.4763miR.483.3p0.0 (−1.5, 1.4)−1.0 (−4.1, 0.7)0.2 (−1.0, 1.6)−0.5 (−2.4, 0.2)0.7130.00180.66640.92090.01160.7726[^4]

3.5. Validation of a potential regulatory association between miR-145-5p and miR-483-5p/3p {#sec3.5}
------------------------------------------------------------------------------------------

While revising the recent literature for the predictive miRNAs, we uncovered a potential mechanistically-relevant link between IIT response-predictive miR-145-5p and miR-483-5p/3p (the sense and corresponding antisense miRNAs originating from the same primary miR-483). The latter miRNAs were not originally included in our panel. Specifically, miR-145-5p and miR-483-3p are reported to be involved in a glucose level-dependent loop that regulates miR-145-induced TP53-dependent cell death in hepatocellular carcinoma [@bib52]. On the other hand, the complementary strand miR-483-5p has been reported to be differentially expressed in pancreatic α and β cells, and to protect against proinflammatory cytokine-induced apoptosis of β cells in culture and in mice, while increasing insulin transcription and secretion by the β cells and reducing glucagon transcription and secretion by the α cells [@bib53]. Therefore, we hypothesized that the miR-145/miR-483 regulatory loop may play a mechanistic role contributing to the response to short-term IIT in humans. To assess the potential association between miR-145-5p and miR-483 in humans with diabetes, we then profiled both miR-483-3p and miR-483-5p in this study\'s plasma samples using TaqMan^®^ assays and quantitative real time PCR (these measurements were normalized against the expression of the internal/endogenous control miR-191, [Figure 2](#fig2){ref-type="fig"}A, D). Supporting our hypothesis, we found that circulating levels of miR-483-5p significantly negatively correlated with circulating levels of miR-145-5p (r = −0.34, *P* = 0.0203, [Figure 2](#fig2){ref-type="fig"}B) and positively with miR-192-5p (an IIT-responsive miRNA reported in the next section, r = 0.38, *P* = 0.009, [Figure 2](#fig2){ref-type="fig"}C). Remarkably, the baseline circulating levels of miR-483-5p significantly correlated (absolute \|r\| \> 0.3 and *P* \< 0.05) with the baseline levels and the change in levels of HbA1c, fasting insulin, HOMA IR, AUC of the response to glucagon ([Figure 2](#fig2){ref-type="fig"}H--G), as well as with the change in fasting glucose levels ([Figure 2](#fig2){ref-type="fig"}L). On the other hand, levels of miR-483-5p expectedly and highly significantly correlated with the levels of miR-483-3p (r = 0.53, *P* = 1.30 × 10^−04^, [Figure 2](#fig2){ref-type="fig"}E), and the levels of miR-483-3p highly significantly negatively correlated with the levels of miR-29c-3p, the other IIT response-predictive miRNA (r = −0.58, *P* = 2.32 × 10^−05^, [Figure 2](#fig2){ref-type="fig"}F) and with miR-195-5p (an IIT-responsive miRNA reported in the next section, r = −0.47, *P* = 0.001, [Figure 2](#fig2){ref-type="fig"}G). Despite these strong correlations with clinical changes relevant to the response to short-term IIT, when baseline normalized miR-483 data was included among the set of baseline variables used to generate the RF classifiers and the BSE iterative RF process repeated, the optimal RF classifier continued to be comprised of the same three variables, namely miR-145-5p, miR-29c-3p, and HbA1c.Figure 2Expression profiling of miR-483-5p and miR-483-3p in circulation of humans with type 2 diabetes. Quantitation using real time PCR and TaqMan^®^ assays. Measurements were normalized against the expression of the internal/endogenous control miR-191. Blue and orange circles represent nonresponder (NR) and responder (R) group data points, respectively, in panels H--L. Black, red, green, and blue represent nonresponder-post, nonresponder-pre, responder-post, and responder-pre, respectively, in panels E**--**G.Figure 2

3.6. Circulating levels of miR-138-5p, miR-192-5p, miR-195-5p, miR-320b, and let-7a-5p differentially change in response to short-term IIT {#sec3.6}
------------------------------------------------------------------------------------------------------------------------------------------

To gain insight into potential miRNA-regulated mechanisms in response to short-term IIT, we evaluated the baseline and four-week follow-up changes in circulating miRNA levels and assessed the correlations between these changes and the changes in clinically relevant measures of beta-cell function (*i.e.*, ISSI-2 and ΔISR~0-120~/ΔGluc~0-120~×Matsuda index), insulin resistance (*i.e.*, HOMA-IR), glycemic control (*e.g.*, HbA1c), and glucagon response (*e.g.*, AUC glucagon). We anticipated that changes in short-term IIT-responsive miRNAs would track with improvements in beta-cell function and insulin sensitivity, among others.

As shown in [Table 2](#tbl2){ref-type="table"}, five circulating miRNAs (Pattern A: miR-138-5p, miR-192-5p, miR195-5p, miR-320b, and let-7a-5p) displayed significant differential expression changes (as denoted by the significant Group-by-Time interactions (*P* \< 0.05 and FDR ≤ 0.2)) in response to short-term-IIT. This effect was due to changes in the plasma miRNA levels either only in one of the groups or in opposite directions in both R and NR groups ([Figure 3](#fig3){ref-type="fig"}A--E, [Supplementary Figure SF4](#appsec4){ref-type="sec"}). In contrast to miR-145-5p and miR-29c-3p, which did not significantly change with treatment but were predictive of treatment response at baseline, Pattern A miRNAs did not significantly differ at baseline (as evidenced by their non-significant group effects) but changed in response to short-term IIT and their changes effectively separated responders from nonresponders as assessed by PCA ([Table 2](#tbl2){ref-type="table"}, [Figure 3](#fig3){ref-type="fig"}A--F). Interestingly, the changes in let-7a-5p, miR-195-5p, miR-320b, and miR-138-5p appear coregulated to some extent, as suggested by significant (\|r\| \> 0.4, *P* \< 0.05) and marginally significant (\|r\| \> 0.4, *P* ≤ 0.062) correlations among them ([Figure 3](#fig3){ref-type="fig"}G--I). Of note, the changes in the circulating levels of Pattern A miRNAs significantly correlated (see [Figure 4](#fig4){ref-type="fig"}) with changes in measures of β-cell function (r~ΔmiR.192∼ΔISSI2~ = −0.51, *P* = 0.024; r~ΔmiR.138∼Δ(ΔISR0..120/Δgluc0..120× = 0.48~, *P* = 0.039; and r~ΔmiR.320b∼ΔISSI2~ = −0.48, *P* = 0.037; all with FDR \< 0.10), insulin resistance (r~ΔmiR.192∼ΔHOMA.IR~ = 0.69, *P* = 0.001, FDR \< 0.01), and fasting insulin (r~ΔmiR.192∼Δfasting.insulin~ = 0.69, *P* = 0.001, FDR \< 0.01). The change in levels of miR-192-5p and miR-195-5p additionally tracked with the change in measures of whole body composition (r~ΔmiR.192∼ΔWaist.circumference~ = 0.56, *P* = 0.012; r~ΔmiR.192∼ΔBMI~ = 0.46, *P* = 0.046; and r~ΔmiR.195∼ΔBMI~ = −0.49, *P* = 0.034, all with FDR \< 0.10, [Figure 4](#fig4){ref-type="fig"}F,H). miR-195-5p displayed an additional trend with fasting glucose (r~ΔmiR.195∼\ Δfasting.glucose~ = −0.44, *P* = 0.062, FDR \< 0.1). MiRNAs with a second pattern of change displaying significant Time effect but nonsignificant Group-by-Time interaction (Pattern B, [Table 2](#tbl2){ref-type="table"}, [Supplementary Figures SF4 and SF5](#appsec4){ref-type="sec"}), were also identified.Figure 3Longitudinal changes and correlations in microRNAs (miRNAs) that significantly change in response to short-term intensive insulin therapy (IIT). (**A--E**) Pattern A miRNAs with significant Group-by-Time interaction (*P* \< 0.05, FDR \< 0.2). Data presented as quantile-normalized log2 fold changes relative to the median of the nonresponders group at pre-IIT (NR.Pre) time point. The connected dots represent corresponding pre-therapy and post-therapy measurements for each individual participant (R: Responder group, orange filling; NR: Nonresponder group, blue filling; n = 12 per group). In the boxplots, the box delineates the first and third quartiles (the interquartile range, IQR), whereas the whiskers delineate the smallest and largest values inside a 1.5 box-length from the end of the box. The boxplot summarizes the data presented in the corresponding side-by-side dot plot, while the dot plot reveals valuable information about the longitudinal changes taking place per subject. Note that some samples have similar normalized logFC values, therefore multiple lines may converge onto a single dot. The number of lines, not the number of dots, represents the number of samples contributing data for the specific plot. Red dots represent data points located at greater than 1.5 IQR from the end of the box. Blue filling used for NR group and orange filling for R group. (**F**) Principal component analysis plot based on changes in Pattern A miRNAs effectively separate the responders from the nonresponders subjects. (**G--I**) Correlated changes in the circulating levels of Pattern A miRNAs in response to short-term IIT.Figure 3Figure 4Correlations between changes in Pattern A circulating miRNA levels and changes in relevant clinical variables and indices of interest. Partial correlations calculated using the *ppcor* R package and adjusting for age, duration of diabetes, baseline HbA1c, and baseline AUC glucagon. Blue-filled circles represent individual values for the Nonresponder (NR) group. Orange-filled circles represent individual values for the Responder (R) group.Figure 4

3.7. A network of cooperatively regulated validated miRNA targets is enriched in genes that regulate cell death and proliferation {#sec3.7}
---------------------------------------------------------------------------------------------------------------------------------

To gain additional general mechanistic insight, we assessed the functional relevance of the putative network of genes targeted (supported by strong experimental evidence, specifically reporter assay or western blot) by both the IIT predictive and responsive miRNAs (denoted herein as IIT miRNAs). The IIT miRNA-target gene network analysis identified a total of 1672 genes that are experimentally demonstrated to physically interact with at least one of the IIT miRNAs (note that there were no targets with strong validation support in the miRTarBase database for miR-483-5p/3p --therefore, these miRNAs do not appear in our [Figure 5](#fig5){ref-type="fig"} network). Remarkably, 109 of those (6.5%, *P* = 0.0306 as empirically determined by comparison to 10000 simulated equivalent random networks) are targeted by more than one IIT miRNAs ("cooperatively targeted") ([Supplementary Table ST3](#appsec4){ref-type="sec"}). Furthermore, 91 of the cooperatively targeted genes were significantly overtargeted by the IIT miRNA set (hypergeometric *P* \< 0.05 and FDR \< 0.05, as compared to targeting proportions in the interaction universe/background, [Supplementary Table ST3](#appsec4){ref-type="sec"}, interaction network shown in [Figure 5](#fig5){ref-type="fig"}A). Consequently, this relatively large number of overtargeted genes was also highly significant (*P* = 0.0039, as empirically determined by comparison to 10000 simulated equivalent random networks). As shown in [Figure 4](#fig4){ref-type="fig"}, [Figure 5](#fig5){ref-type="fig"}B, the overtargeted gene network depicted a 9-gene central cluster including BCL2, CDK6, SPTBN1, DICER1 (these four genes targeted by four IIT miRNAs each), RPS6KB1 SERPINE1, SENP1, CDC25A, and SIRT1 (these five genes targeted by three IIT miRNAs each). Gene set enrichment analysis (for GO biological processes) highlighted the enrichment in overtargeted genes that regulate cell death, cell cycle, proliferation, and cell and tissue morphogenesis, among the most relevant processes ([Figure 5](#fig5){ref-type="fig"}C,D, [Supplementary Tables ST4 and ST5](#appsec4){ref-type="sec"}).Figure 5Functional network analysis. (**A**) Network of experimentally validated interactions between seven IIT miRNAs and corresponding 91 overtargeted genes. Overtargeted genes appear to interact with a significantly higher number of miRNAs than expected by chance (as determined by hypergeometric tests of network proportions compared to the respective proportions in the miRNA--target interaction universe/background). (**B**) Enrichment of gene ontology annotations among the complete set of 91 overtargeted genes (method set to 'slim' annotations and significance value cutoff Padj \< 0.05). (**C**) Re-drawn subnetwork for the central cluster of 9 highly overtargeted genes (3 or more targeting miRNAs per gene) and interacting set of six IIT miRNAs. (**D**) Enrichment of gene ontology annotations for the central cluster of 9 overtargeted genes (method set to 'all' annotations and significance value cutoff Padj \< 0.001). Categories with the lowest *P* values at the bottom of the plot. Annotation enrichment analysis was assessed using the *GOCluster_Report* function of the *systemPipeR* package in the R environment.Figure 5

4. Discussion {#sec4}
=============

In this study, we provide evidence of a predictive multimodal signature in patients with early type 2 diabetes who were treated with short-term IIT. In addition, the longitudinal comparison of circulating miRNA levels between the group with considerable reversibility in beta-cell dysfunction in response to short-term IIT (the R group) and the group without such reversibility (the NR group), provides insights into potential underlying regulatory mechanisms determining the response to short-term IIT. A hallmark of reversibility of beta-cell dysfunction in early type 2 diabetes is the coupling of a high HbA1c with short duration of diabetes [@bib3], [@bib5], [@bib11]. This situation arises because of the effect of glucotoxicity in amplifying the rise in glycemia that characterizes the natural history of type 2 diabetes. Specifically, early in the course of the disease, glycemia increases as beta-cell function worsens. When glucose levels reach the glucotoxic threshold at which they further compromise beta-cell function \[*i.e.*, first-phase insulin secretion is abolished at blood glucose 6.4 mmol/l [@bib54]\] there will be an amplification of beta-cell dysfunction and a more rapid rise in glycemia. While the resultant effect is one of higher glycemia in early type 2 diabetes, its emergence is indicative of reversible beta-cell dysfunction (*e.g.*, due to glucotoxicity). For this reason, it was expected that, compared to nonresponders, the responders may have shorter duration of diabetes coupled with higher HbA1c.

4.1. Predictive value of baseline circulating levels of miR-145-5p, miR-29c-3p, and HbA1c {#sec4.1}
-----------------------------------------------------------------------------------------

Using an implementation of the RF algorithm described by Breiman [@bib30], which reduces bias and is protected from overfitting, we demonstrated that baseline levels of miR-145-5p, miR-29c-3p, and HbA1c could accurately and sensitively predict the response to short-term IIT. This was further evidenced by the significant correlations between miR-145-5p baseline levels and the changes in measures of beta-cell function (ISSI-2) and glycemic control (fasting glucose and HbA1c). Although these associations do not demonstrate causality, they suggest that the lower the baseline levels of miR-145-5p, the larger the increase in ISSI-2 and the larger the reduction in fasting glucose and HbA1c levels. Consistent with our findings, the parent trial found that higher baseline HbA1c levels may predict response to short-term IIT [@bib11]. Importantly, no combination of clinical parameters demonstrated better performance than that of the multimodal RF classifier. This highlights the utility of profiling miRNA biomarkers alongside clinical parameters to predict response and aid selection of anti-diabetic therapies.

Based on validated functions of miR-145-5p (discussed below) and the correlations observed in our study, we speculate that baseline levels of this miRNA may reflect the "irreversible component" (*e.g.*, dying beta-cell mass) that affects the response to short-term IIT. Notably, expression of miR-145-5p (originally considered a cardiovascular-specific miRNA) has been found to be upregulated in the liver, muscle, and pancreas of db/db obese mice [@bib55], to be regulated by glucose concentration and to be involved in glucose homeostasis through regulation of ABCA1 and cholesterol efflux in liver and pancreas [@bib56], and to be upregulated by resistin (an adipocyte-derived cytokine associated with insulin resistance) both *in vivo* and *in vitro*, consequently impairing insulin signaling [@bib57]. Other studies have found that miR-145-5p increases lipolysis in human adipocytes through increased production and processing of pro-inflammatory TNF-α [@bib58]. Remarkably, miR-145-5p was also recently reported to induce, depending on glucose availability, either inhibitory or stimulatory effects on the apoptotic rate of hepatocellular carcinoma [@bib52]. In that work, Lupini and colleagues demonstrated that miR-145-5p induced downregulation of \[oncogenic\] miR-483-3p under low-glucose and up-regulation under high-glucose conditions, which translated into induction or inhibition of miR-145-induced TP53-dependent apoptosis, respectively [@bib52]. The authors also reported the existence of a regulatory loop between miR-145-5p and miR-483-3p in normal cells, which is lost in tumor cells. On the other hand, Mohan and colleagues reported that miR-483-5p (the mature miRNA from the forward strand) respond to elevated glucose levels and is overexpressed in pancreatic beta cells (as compared to alpha cells, both *in vitro* and *in vivo*), and that overexpression of miR-483-5p induces insulin secretion and inhibits glucagon secretion through activation of insulin signaling [@bib53]. These authors also reported that overexpression of miR-483-5p protects against cytokine-mediated apoptosis in beta cells and is consequently elevated in prediabetic mice islets in correspondence with the increase in beta cell mass. Extrapolating to our study scenario, we hypothesize that the lower glucose levels in subjects of the nonresponder group (which are in "more advanced" stages of early type 2 diabetes, with longer duration of diabetes and with lower glycemia), together with putative higher baseline miR-145-5p tissue levels, may "reinforce" the activity of the regulatory loop by which miR-145-5p represses miR-483 (both -5p and -3p) activities, therefore augmenting the rate of miR-145-induced apoptosis and presumably the demise of beta cells in the pancreas. On the other hand, the higher levels of blood glucose in subjects in the responder group (in "earlier" stages of early type 2 diabetes, with higher glycemia due to the stronger influence of reversible glucotoxicity and lower miR-145-5p baseline levels), may induce the upregulation of miR-483 activities, which consequently counteract the pro-apoptotic functions of miR-145 and presumably stimulates proliferation of beta cells in the pancreas. The consequent improvement in beta cell function in the responder group would then contribute to reversing glucotoxicity and lowering glycemic levels, consequently inducing the observed rising trend in miR-145-5p and correspondingly decreasing trend in miR-483-5p after short-term IIT. We hypothesize that the balanced interplay among these miRNAs and respective regulated genes, in a tissue-specific physiological/pathophysiological context are important determinants of disease progression and response to therapy in subjects with type 2 diabetes. These results represent an indirect validation of the occurrence of the regulatory loop between miR-145-5p and miR-483-3p/5p in tissues (likely the pancreas and/or liver) from humans with type 2 diabetes and indicate that baseline levels of miR-483-5p in circulation can also be predictive of the response to short-term IIT. Furthermore, Cui and colleagues recently demonstrated that downregulation of miR-145-5p in diabetes-bone marrow stromal-cells (diabetes-BMSCs) increased cell proliferation and decreased cell death in addition to improving vascular remodeling in the ischemic rat brain [@bib59]. We speculate that, in a somewhat similar fashion, people with type 2 diabetes that have lower levels of miR-145-5p (as in our R group) may experience reduced beta-cell death, improved proliferation, and an improved vasculogenic microenvironment in the pancreas that, therefore, may elicit a positive response to short-term IIT.

On the other hand, miR-29, one of the most abundant miRNA family in human pancreatic β-cells and in the liver [@bib60], has been reported to be downregulated under hyperinsulinemic conditions (*e.g.*, in the heart, possibly as an adaptive mechanism to protect the organ in the prediabetic stage [@bib61]), but increased in response to loss of hyperinsulinemia and elevated plasma glucose levels [@bib62]. However, an apparent inverse correlation between liver and circulating plasma miR-29 levels in type 2 diabetes has also been suggested and deemed intriguing [@bib63]. Although miR-29 did not show significant correlations with relevant clinical measurements in our subjects, we note that responders tend to have higher baseline levels of circulating miR-29. Therefore, considering the reported inverse correlation between circulating and tissue levels for miR-29 in type 2 diabetes, we speculate that responders may have lower levels of miR-29 in some insulin-sensitive tissues, which may provide for additional protection in these subjects and a positive response to the treatment.

4.2. Differential miRNA signature responsive to short-term IIT {#sec4.2}
--------------------------------------------------------------

Five circulating miRNAs, miR-138-5p, miR-192-5p, miR-195-5p, miR-320b, and let-7a-5p, showed significant differential expression changes in response to four-week short-term IIT. Their changes in the subjects\' circulation effectively separated the subjects that responded to the therapy from those that did not, as assessed by PCA. This suggests that short-term IIT induced major changes in the circulating levels of pattern A miRNAs that are defined by the subjects' capacity to respond to the therapy. Those changes also associated with concomitant changes in beta-cell function (as evidenced by significant correlation with the change in ISSI-2), insulin resistance (as evidenced by significant correlation with the change in HOMA IR), and fasting insulin concentrations. This suggests that Pattern A miRNAs may regulate a reversible state, potentially due to glucotoxicity, that is responsive to short-term IIT in people with early type 2 diabetes.

Notably, binding of miR-138-5p to the TATA-box region in the promoter of the insulin gene enhances the promoter activity and consequently the expression of the insulin gene [@bib64]. Therefore, the elevated plasma abundance detected for miR-138-5p in our R group suggests that short-term IIT may increase the expression of the insulin gene in pancreatic beta-cells. On the other hand, miR-192-5p is one of the most abundant miRNAs in pancreatic beta-cells, liver, and kidney [@bib65], [@bib66], and is significantly increased in the circulation in early disease stages, as in people with prediabetes [@bib67]. In addition, roles in insulin resistance, cardiometabolic phenotypes, diabetic nephropathy, and non-alcoholic fatty liver disease (NAFLD) have recently been suggested [@bib68], [@bib69], [@bib70]. Notably, we recently identified miR-192-5p as a key vitamin D-responsive miRNA in subjects with prediabetes [@bib50]. Supporting our findings in this study, miR-192-5p was also reduced by the vitamin D treatment and correlated with the change in fasting plasma glucose [@bib50].

Another subset of Pattern A miRNAs, namely let-7a-5p, miR-195-5p, and miR-320b appeared to be coregulated, as suggested by the significant correlations among them. Consistent with this notion, these three miRNAs have been similarly implicated in diabetes [@bib23], [@bib71], [@bib72], [@bib73], [@bib74], [@bib75], [@bib76], [@bib77], cardiovascular disease [@bib74], [@bib77], [@bib78], [@bib79], and cancer [@bib80], [@bib81], [@bib82], [@bib83], and their effects appear to be associated with the miRNA presence in exosomes [@bib73], [@bib74], [@bib75], [@bib76], [@bib80]. Consistent with our findings, let-7a-5p (a highly abundant miRNA in human β-cells [@bib84]) was found to be significantly downregulated in plasma exosomes from people with type 2 diabetes, significantly correlated with plasma glucose and HbA1c levels, and responsive to antidiabetic treatment [@bib75]. On the other hand, miR-195-5p was found upregulated in the liver of diabetic rats and its expression showed a linear relationship with the glycemic phenotype of three distinct strains, which suggested a role in the pathophysiology of type 2 diabetes [@bib72]. Remarkably, we have recently detected circulating exosomal miR-195-5p changing in diabetic people in response to treatment with pioglitazone [@bib85]. Regarding miR-320b, its upregulation in cultured adipocytes contributed to the development of insulin resistance [@bib71] while in diabetic mice contributed to the development of hyperglycemic/metabolic memory in the heart despite normoglycemia restoration [@bib77]. In addition, family member miR-320a was found to regulate skeletal muscle mitochondrial metabolism [@bib86]. These findings suggest potential clinical utility for the design of new strategies to interfere with the development of hyperglycemic memory in specific tissues. We hypothesize that the implementation of short-term IIT early in the development of type 2 diabetes could contribute to reducing the levels of miR-320b and consequently, interfere with the development of hyperglycemic memory later in the course of the disease, potentially contributing to reduced risk of disease progression and reduced risk of cardiovascular complications, as evidenced in the United Kingdom Prospective Diabetes Study [@bib87].

Collectively, the predictive and responsive miRNAs (IIT miRNAs) define a network of validated miRNA--mRNA interactions that additionally suggests the coordinated regulation of genes that regulate cell proliferation, apoptosis, and cell/tissue morphogenesis. A central cluster of nine overtargeted genes including BCL2, CDK6, SPTBN1, DICER1, RPS6KB1 SERPINE1, SENP1, CDC25A, and SIRT1 (identified from among 91 genes targeted by more than one of the select IIT miRNAs) emerge as potentially key players driving a positive response to the insulin therapy in early diabetic patients. Reduced demise of challenged/dying beta-cells and concomitant enhanced beta-cell proliferation and pancreatic tissue remodeling (morphogenesis) in the diabetic pancreas is a plausible mechanism that could explain, at least in part, the beneficial and long-term effects of short-term IIT in humans with early type 2 diabetes. Interestingly, a recent trans-omic network analysis of selective responses to low (basal) and high (induced) insulin administration (*in vitro* using rat hepatoma cells and *in vivo* using insulin-clamped rat livers) found that basal and induced insulin effects are decoded by the cells via mostly mutually exclusive pathways [@bib88]. However, FoxO1, a key transcription factor inhibited by Akt phosphorylation and activated by Sirt1 deacetylation among other stimuli [@bib89], was able to regulate both basal and induced insulin-responsive transcripts [@bib88]. As SIRT1, which has also been found to be a critical factor for Pdx1 transcription and β cell formation [@bib90], is one of the most significantly overtargeted genes in our analysis and FOXA1 (also activated by Sirt1 and an interdependent binding partner and enhancer of FoxO1 binding to the promoter of insulin-sensitive genes [@bib91]) is also significantly overtargeted by IIT miRNAs (refer to [Figure 5](#fig5){ref-type="fig"} networks and [Supplementary Table ST3](#appsec4){ref-type="sec"}), these results suggest that IIT miRNAs may be functionally involved in the regulation of both the basal and induced cellular responses to insulin. Consequently, deregulation and/or individual variation in IIT miRNA levels may impact the natural history of type 2 diabetes and/or the heterogeneity in response to treatment.

Also notably, DICER1, one of the top overtargeted genes in our network analysis (targeted by 4 of the 7 IIT miRNAs), was recently shown by the Kahn group to play a fundamental role in adipose tissue, which contributes a majority of exosomal miRNAs into the circulation [@bib92]. Additionally, DICER-dependent miRNA biogenesis was shown to be critical to sustain survival and activity of POMC neurons and to mediate hypothalamic regulation of energy balance by relaying peripheral nutrient excess and/or obesity [@bib93], [@bib94]. Of note, the IIT miRNAs also significantly overtarget the PPARG transcript ([Figure 5](#fig5){ref-type="fig"}A), which is a master transcriptional regulator of metabolism and, in particular, critical for fat-cell formation/differentiation of adipose tissue [@bib95], [@bib96], [@bib97]. Importantly, a recent work by Taylor and collaborators demonstrated that substantial (15%) weight loss through a low-calorie diet in subjects with type 2 diabetes can lead to restoration of β cell function in about 2/3 of the intervened population [@bib98]. These authors found that the major difference between their responder and nonresponder groups was the respective ability to recover first-phase insulin response (response to the intervention was then dependent upon the capacity of β cell recovery) and, as in our cohort, that response was predicted by shorter duration of diabetes. Those results, in the context of our work and the work of others discussed here, support the hypothesis that short-term IIT and significant weight loss interventions may similarly improve β cell function, possibly via alterations in adipocyte miRNA release, and contribute to remission of type 2 diabetes.

Pattern B miRNAs, which show a significant Time effect generally due to similar directional changes in both R and NR groups, appear to represent miRNAs modulated by the insulin therapy or glycemia but not causally related to the improvements in insulin secretion and sensitivity evidenced by the change in the ISSI-2 index. These miRNAs may be responsible, at least in part, for the significant reduction of HbA1c levels in both groups. Supporting this reasoning, we and others have previously found several of the Pattern B miRNAs changing in the circulation of people with obesity and/or diabetes (*e.g.*, miR-34a, miR-144, let-7b [@bib18], [@bib19], [@bib22], [@bib24], [@bib51], [@bib99]), and playing mechanistic roles in obesity and glucose metabolism (*e.g.*, miR-15b, miR-802 [@bib100], [@bib101]).

Although we consider these results exciting and promising, there are several limitations in our study. First, the limited cohort size makes validation in independent cohorts important. Second, our study involved people with type 2 diabetes in an early stage in the natural history of the disease, therefore limiting the generalizability to other disease stages. In addition, direct experimental validation of target gene changes and mRNA knockdown/overexpression in human diabetic tissue samples is lacking, which could strengthen our findings by clarifying potential mechanisms. It is not clear, for example, whether the between group differences in the change in miRNA abundance are causally related to changes in blood glucose, insulin secretion, insulin resistance, or changes in some other unmeasured factors. Lastly, beta-cell function and insulin resistance were assessed with OGTT-based surrogate indices instead of with "gold standard" clamp measurements. However, ISSI-2 and HOMA-IR indexes are well-validated measurements used in previous studies [@bib11].

5. Conclusions {#sec5}
==============

In this study, we have generated an accurate multimodal RF classifier with potential clinical utility for predicting responses to short-term IIT among patients with recently diagnosed type 2 diabetes. An important current limitation of short-term IIT is the inability to identify potential responders at baseline. Therefore, we emphasize the potential clinical relevance of our study, as it represents a first step in that context and provides key insight into the pathophysiologic determinants of reversibility of beta-cell dysfunction. Such reversibility cannot be identified by any other conventional measure in use today. This insight may inform targeted therapeutic interventions aimed at ameliorating reversible beta-cell dysfunction and thereby changing the natural history of type 2 diabetes. Whether the specific miRNAs and RF classifier will also be useful to predict responses to antidiabetic therapies is an intriguing question warranting further study.

Author contributions {#appsec1}
====================

A.A.S, R.R., and REP contributed to the conception and design of the research design, analysis plan, supervision of the analysis, study implementation, data acquisition, and interpretation, writing of the manuscript, and critical revision and final approval of the manuscript. Y.O.N.L performed experiments, conducted data analysis, and contributed to data interpretation and writing of the manuscript. R.E.P and B.Z. contributed to the study design, study implementation, data interpretation, and critical revision and final approval of the manuscript. A.A.S is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Prior presentation {#appsec2}
==================

None.

Conflict of interests/Disclosure summary {#appsec3}
========================================

This study was funded by startup funds granted to A.S. and R.E.P by Florida Hospital. The LIBRA trial was funded by Novo Nordisk as an investigator-initiated trial to R.R. and B.Z.. R.R. and B.Z. have received consulting honoraria and research support from Novo Nordisk. REP has received research grants (to his institution) from Lexicon Pharmaceuticals, Ligand Pharmaceuticals, Inc., Lilly, Merck, Novo Nordisk, Sanofi-Aventis US, LLC, and Takeda and has previously received speaker and/or consultancy fees (to his institution) from AstraZeneca, Boehringer Ingelheim, Eisai, Inc., GlaxoSmithKline, Hanmi Pharmaceutical Co., Ltd., Janssen Scientific Affairs, LLC, Ligand Pharmaceuticals, Inc., Lilly, Merck, Novo Nordisk, Pfizer, Sanofi and Takeda. No other potential conflicts of interest relevant to this article were reported.

Appendix A. Supplementary data {#appsec4}
==============================

The following is the supplementary data to this article:Multimedia component 1Multimedia component 1

We would like to thank Florida Hospital for granting funds to A.S. and R.E.P. to conduct this study. The LIBRA trial (parent study) was funded by Novo Nordisk as an investigator-initiated trial to R.R. and B.Z. R.R holds the Boehringer Ingelheim Chair in Beta-cell Preservation, Function and Regeneration at Mount Sinai Hospital.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.molmet.2018.11.003>.

[^1]: Current address: Fox Chase Cancer Center, Temple Health, Temple University, 333 Cottman Avenue, Philadelphia, PA, USA. Fax: +1 215 214 1590.

[^2]: Data sqrt^(†)^ or log^(§)^ transformed to approximate normality for statistical inference tests.

[^3]: Unadjusted differences in baseline measures were determined using the Welch two sample t test (for continuous variables) or the Fisher exact test (for categorical variables). Data is presented as mean with standard deviation or as percentage (%). Standard Pearson\'s correlation between baseline levels of clinical/metabolic variables and the percent change in ISSI-2 were calculated to identify potential confounding covariates.

[^4]: Pattern A miRNAs are characterized by significant Group-by-Time interaction effects (Fold Change \> 2, *P* \< 0.05 and FDR ≤ 0.2028), generally due to changes either in only one of the groups or in opposite directions in both R and NR groups. Pattern B miRNAs are characterized by significant Time effect (Fold Change \> 2, *P* \< 0.05 and FDR \< 0.1), generally due to either a significant reduction or significant increase in plasma levels in both R and NR groups. Predictive miRNAs (as part of an RF classifier), although not considered differentially expressed by the study design criteria, are able to predict response to short-term IIT at baseline (pre-treatment stage). Both strands of miR-483 (-5p/-3p, potentially involved in regulatory loop with miR-145-5p) are stably detected and highly correlated among themselves and with miR-145-5p and miR-29c, respectively. Data is presented as median log2 fold change \[relative to the median of the NR group baseline (Pre-IIT time point)\], with 95% confidence interval in parenthesis. FDR calculated using the Benjamini-Hochberg correction.
